Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ""Sumatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( )] 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( )] 5.2 History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke ee [s Warnings and Precautions ( )] 5.4 Peripheral vascular disease [see Warnings and Precautions ( )] 5.5 Ischemic bowel disease [see Warnings and Precautions ( )] 5.5 Uncontrolled hypertension [see Warnings and Precautions ( )] 5.8 Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT ) agonist 1 [see Drug Interactions ( , )] 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions ( ) and Clinical Pharmacology ( )] 7.2 12.3 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions ( )] 5.9 Severe hepatic impairment [see Use in Specific Populations ( ) and Clinical Pharmacology ( )] 8.6 12.3 History of coronary artery disease or coronary artery vasospasm ( ) 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( ) 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( ) 4 Peripheral vascular disease ( ) 4 Ischemic bowel disease ( ) Uncontrolled hypertension ( ) 4 4 Recent (within 24 hours) use of another 5-HT agonist (e.g., another triptan) or of an ergotamine-containing medication. ( ) 1 4 Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor. ( ) 4 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen). ( ) 4 Severe hepatic impairment. ( ) 4"" ?g. }

• association label ""Sumatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( )] 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( )] 5.2 History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke ee [s Warnings and Precautions ( )] 5.4 Peripheral vascular disease [see Warnings and Precautions ( )] 5.5 Ischemic bowel disease [see Warnings and Precautions ( )] 5.5 Uncontrolled hypertension [see Warnings and Precautions ( )] 5.8 Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT ) agonist 1 [see Drug Interactions ( , )] 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions ( ) and Clinical Pharmacology ( )] 7.2 12.3 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions ( )] 5.9 Severe hepatic impairment [see Use in Specific Populations ( ) and Clinical Pharmacology ( )] 8.6 12.3 History of coronary artery disease or coronary artery vasospasm ( ) 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( ) 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( ) 4 Peripheral vascular disease ( ) 4 Ischemic bowel disease ( ) Uncontrolled hypertension ( ) 4 4 Recent (within 24 hours) use of another 5-HT agonist (e.g., another triptan) or of an ergotamine-containing medication. ( ) 1 4 Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor. ( ) 4 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen). ( ) 4 Severe hepatic impairment. ( ) 4"" assertion.